Association of Geriatric Nutritional Risk Index With Adverse Event and Treatment Duration in Adjuvant Chemotherapy for Patients With Colorectal Cancer

Atsuya Shimizu,Miyu Fukasawa,Ryosuke Endo,Takumi Nakamura,Shogo Yamada,Ryo Fujibayashi,Ken Kikuchi,Masaomi Tanaka,Isao Hasegawa,Hideki Sato
DOI: https://doi.org/10.21873/invivo.13459
In Vivo
Abstract:Background/aim: In recent years, the Geriatric Nutritional Risk Index (GNRI) has been reported as a predictor of prognosis in many patients with cancer. This study investigated the association of preoperative GNRI with the occurrence of adverse events and duration of treatment with capecitabine plus oxaliplatin (CAPOX), a postoperative adjuvant chemotherapy, in 59 patients with colorectal cancer from September 2019 to April 2022. Patients and methods: A cut-off value of 100.9 was used to categorize patients into high and low GNRI groups. Results: The incidence of grade ≥2 leukopenia (p=0.03), and all grades peripheral neuropathy (p=0.04) were significantly more frequent in the low GNRI group. Analysis of factors influencing treatment duration by univariate and multivariate Cox regression proportional hazards models showed a significant difference in GNRI (p=0.0097). Conclusion: GNRI, a nutritional indicator assessed before the start of treatment, influences the occurrence of adverse events and duration of treatment with CAPOX as adjuvant chemotherapy. To complete CAPOX therapy, preoperatively, it is important to assess the patients' nutritional status using the GNRI and to actively intervene in nutritional therapy.
What problem does this paper attempt to address?